Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 3/2011

01-03-2011

Effect of Calcium and the Calcimimetic AMG 641 on Matrix-Gla Protein in Vascular Smooth Muscle Cells

Authors: Francisco J. Mendoza, Julio Martinez-Moreno, Yolanda Almaden, Maria E. Rodriguez-Ortiz, Ignacio Lopez, Jose Carlos Estepa, Charles Henley, Mariano Rodriguez, Escolastico Aguilera-Tejero

Published in: Calcified Tissue International | Issue 3/2011

Login to get access

Abstract

Vascular calcification (VC) is frequently observed in patients with chronic renal failure and appears to be an active process involving transdifferentiation of vascular smooth muscle cells (VSMCs) to osteoblast-like cells. Reports of VC prevention in uremic rodents by calcimimetics coupled with identification of the calcium-sensing receptor (CaSR) in VSMCs led us to hypothesize that CaSR activation in arterial cells and VSMCs may elicit expression of an endogenous inhibitor of VC. Toward this end, we determined the effects of calcium and the calcimimetic AMG 641 on arterial wall and isolated VSMC expression of matrix-Gla protein (MGP). Bovine VSMCs were incubated with increasing calcium chloride or AMG 641 concentrations, while in vivo experiments were carried out on healthy and uremic rats. Both AMG 641 and hypercalcemia induced MGP expression in the arterial wall in healthy and uremic rats. The results obtained in vitro supported those from in vivo experiments. In conclusion, selective CaSR activation, either by extracellular calcium or AMG 641, increased MGP expression in vivo in the arterial wall and in vitro in bovine VSMCs. This local upregulation of MGP expression provides one potential mechanism by which calcimimetics prevent VC.
Literature
1.
Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161–1170PubMedCrossRef
2.
Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRef
3.
Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68:429–436PubMedCrossRef
4.
Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRef
5.
6.
7.
Steitz SA, Speer MY, Curing G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli GM (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89:1147–1154PubMedCrossRef
8.
Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138PubMed
9.
London GM, Drueke TB (1997) Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51:1678–1695PubMedCrossRef
10.
Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, Ward S, Lacey DL, Martin D (2006) Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 79:431–442PubMedCrossRef
11.
Moe SM, Reslerova M, Ketteler M, O’Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67:2295–2304PubMedCrossRef
12.
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 386:78–81PubMedCrossRef
13.
Price P, Otsuka A, Poser J, Kristaponis J, Raman N (1976) Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 73:1447–1451PubMedCrossRef
14.
Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL (1998) Calcification of human vascular cells in vitro is correlated with high levels of matrix gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 18:379–388PubMed
15.
Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmons M, Weissberg PL (2000) Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol 89(Suppl 2):63–68PubMedCrossRef
16.
Spronk HMH, Soute BAM, Schurgers LJ, Cleutjens JPM, Thijssen HHW, De Mey JGR, Vermeer C (2001) Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 289:485–490PubMedCrossRef
17.
Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, Gardiner RM, Chung E (1999) Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 21:142–144PubMedCrossRef
18.
Price PA, Faus SA, Williamson MK (1998) Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18:1400–1407PubMed
19.
Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drüeke TB, Massy ZA (2009) The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE−/−) mice. Atherosclerosis 205:55–62PubMedCrossRef
20.
Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M (2006) Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17:795–804PubMedCrossRef
21.
De Francisco AL, Izquierdo M, Cunningham J, Piñera C, Palomar R, Fresnedo GF, Amado JA, Unzueta MG, Arias M (2008) Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 23:2895–2901PubMedCrossRef
22.
Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M (2008) The effect of calcitriol, paricalcitol and calcimimetic AMG 641 on extraosseous calcifications in uremic rats. Kidney Int 73:300–307PubMedCrossRef
23.
Garfia B, Cañadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, Rodriguez M (2003) Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 13:2945–2952CrossRef
24.
Price PA, Faus SA, Williamson MK (2000) Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20:317–327PubMed
25.
Chomczynski P, Sacchi N (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1:581–585PubMedCrossRef
26.
Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E (2006) Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 21:484–490PubMedCrossRef
27.
Jono S, Nishizawa Y, Shioi A, Morii H (1998) 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98:1302–1306PubMed
28.
Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL (1994) High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393–2402PubMedCrossRef
29.
Mori K, Shioi A, Jono S, Nishizawa Y, Morii H (1998) Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett 433:19–22PubMedCrossRef
30.
Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM (2000) Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 277:736–740PubMedCrossRef
31.
Nakatani S, Mano H, Ryanghyok IM, Shimizu J, Wada M (2006) Excess magnesium inhibits excess calcium-induced matrix-mineralization and production of matrix gla protein (MGP) by ATDC5 cells. Biochem Biophys Res Commun 348:1157–1162PubMedCrossRef
32.
Farzaneh-Far A, Weissberg PL, Proudfoot D, Shanahan CM (2001) Transcriptional regulation of matrix gla protein. Z Kardiol 3:38–42
33.
Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D (2007) Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 293:F946–F955PubMedCrossRef
34.
Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin D, Ward DT, Alexander MY, Riccardi D, Canfield AE (2009) Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 81:260–268PubMedCrossRef
35.
Molostvov G, Fletcher S, Bland R, Zehnder D (2008) Extracellular calcium-sensing receptor mediated signalling is involved in human vascular smooth muscle cell proliferation and apoptosis. Cell Physiol Biochem 22:413–422PubMedCrossRef
36.
Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, Terwilliger EF, Brown EM, Haunso S, Tfelt-Hansen J (2006) Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 348:1215–1223PubMedCrossRef
37.
Suttamanatwong S, Jensen ED, Schilling J, Franceschi RT, Carlson AE, Mansky KC, Gopalakrishnan R (2009) Sp proteins and Runx2 mediate regulation of matrix Gla protein (MGP) expression by parathyroid hormone. J Cell Biochem 107:284–292PubMedCrossRef
38.
Zebboudj AF, Shin V, Boström K (2003) Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 90:756–765PubMedCrossRef
39.
Koos R, Krueger T, Westenfeld R, Kühl HP, Brandenburg V, Mahnken AH, Stanzel S, Vermeer C, Cranenburg EC, Floege J, Kelm M, Schurgers LJ (2009) Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 101:706–713PubMed
40.
Schurgers LJ, Cranenburg ECM, Vermeer C (2008) Matrix-Gla protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 100:593–603PubMed
Metadata
Title
Effect of Calcium and the Calcimimetic AMG 641 on Matrix-Gla Protein in Vascular Smooth Muscle Cells
Authors
Francisco J. Mendoza
Julio Martinez-Moreno
Yolanda Almaden
Maria E. Rodriguez-Ortiz
Ignacio Lopez
Jose Carlos Estepa
Charles Henley
Mariano Rodriguez
Escolastico Aguilera-Tejero
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 3/2011
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-010-9442-4

Other articles of this Issue 3/2011

Calcified Tissue International 3/2011 Go to the issue

Original Research

Role of Melastatin Transient Receptor Potential 7 Channels in the Osteoblastic Differentiation of Murine MC3T3 Cells

Original Research

Increased Fracture Risk in Normocalcemic Postmenopausal Women with High Parathyroid Hormone Levels: A 16-Year Follow-Up Study

Original Research

Steady and Oscillatory Fluid Flows Produce a Similar Osteogenic Phenotype

Original Research

Localization and Expression of Prothrombin in Rodent Osteoclasts and Long Bones

Original Research

Are Antiresorptive Drugs Effective Against Fractures in Patients with Diabetes?

Original Research

Interplay Between Serum Osteocalcin and Insulin Sensitivity in Primary Hyperparathyroidism
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits